GlassScriptPhysician profile
James S Buck
NPI 1164427555
$720.73
in general payments reported to CMS, 2019-2025
13 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.52 · 2020: $14.35 · 2021: $85.07 · 2022: $115 · 2023: $109 · 2024: $162 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.98 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $221.30 | 2024-2025 | Zurzuvae |
| Organon LLC | $118.39 | 2022-2025 | Nexplanon, Jada System |
| Medtronic, INC. | $66.24 | 2021 | |
| Merck Sharp & Dohme LLC | $57.93 | 2019-2020 | |
| Abbvie INC. | $56.37 | 2019-2025 | |
| Karl Storz Endoscopy-America | $37.83 | 2023 | Image1 Connect |
| Pfizer INC. | $37.70 | 2023-2024 | |
| Agiliti Surgical, INC. | $25.36 | 2022 | |
| Hologic Sales and Service, LLC | $25.34 | 2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Sumitomo Pharma America, INC. | $20.99 | 2025 | Myfembree |
| Sage Therapeutics, LLC | $20.24 | 2022 | |
| Therapeuticsmd, INC. | $18.83 | 2021 | |
| Axonics, INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.